Breaking Down Suzuken Co., Ltd. Financial Health: Key Insights for Investors

Dive into Suzuken Co., Ltd.'s financial snapshot: fiscal-year net sales edged up 0.6% to ¥2,399,952 million (FY Mar 31, 2025) after a steady multi-year growth trend, while profit attributable to owners jumped 18.9% to ¥34,496 million; operating profit reached ¥23,934 million (operating margin 1.30%) and net income was ¥28,763 million, with ROA (TTM) at 1.98% and ROE (TTM) at 8.38% signaling measured efficiency; the balance sheet shows total assets of ¥1,021,155 million and net assets of ¥271,567 million with a capital adequacy ratio of 26.6%, cash reserves of ¥141,581,991,936 bolster liquidity, dividends rose from ¥40.00 to ¥50.00 per share and active buybacks (427,800 shares in June 2025, 358,400 in September 2025 toward a 5.2 million‑share plan) target shareholder value; valuation metrics (market cap ¥373.81 billion, trailing P/E 11.46, forward P/E 16.79, price-to-book 0.92) and a YTD share gain of 30.67% frame the investment debate-read on for a detailed breakdown of revenue trends, profitability metrics, capital structure, liquidity, valuation, risks and growth levers that investors need to weigh.

Suzuken Co., Ltd. (9987.T) - Revenue Analysis

• Net sales FY2025: ¥2,399,952 million (up 0.6% vs. ¥2,386,493 million in FY2024)
• First half FY2025 net sales: ¥1,219,440 million (up 1.8% year-over-year)
• Revenue growth history: +3.67% in FY2023, +3.1% in FY2024, +0.6% in FY2025 - demonstrating persistent, if decelerating, expansion
• Profit attributable to owners of the parent FY2025: ¥34,496 million (up 18.9%)
• Revenue per share (TTM): ¥31,625.75

• Growth context: The company's incremental revenue gains in FY2025 (+0.6%) follow stronger mid-cycle increases in prior years, signalling stability in demand for pharmaceutical distribution services while margins expanded materially (reflected in the +18.9% jump in profit attributable to owners).
• Operational cadence: H1 FY2025 growth of 1.8% to ¥1,219,440 million indicates continued momentum through the year's first six months, supporting the full-year outcome.
• Investor-relevant metric: TTM revenue per share of ¥31,625.75 offers a per-share perspective for valuation comparisons and highlights market exposure to Suzuken's revenue base.

Suzuken Co., Ltd. (9987.T) - Profitability Metrics

• Operating profit (FY2025): ¥23,934 million - +1.3% year-over-year.
• Operating margin (FY2025): 1.30% - indicates focused cost management on large revenue base.
• Net income attributable to owners of the parent (FY2025): ¥28,763 million - +0.8% year-over-year.
• Net profit margin (FY2025): ≈1.44% - reflects modest but positive bottom-line conversion.
• Return on assets (TTM): 1.98% - asset base generating modest returns.
• Return on equity (TTM): 8.38% - shareholders' equity producing mid-single-digit returns.
• First half FY2025: profit attributable to owners of the parent declined 19.9% - early-period weakness offset by full-year resilience.

• Profitability drivers: stable prescription drug distribution margins, efficiency gains in logistics and procurement, and controlled SG&A growth.
• Risks to margins: pricing pressure from government reimbursement adjustments, inventory/working capital strains, and episodic non-operating gains/losses.
• Operational implication: modest operating margin (1.30%) means incremental revenue growth and cost discipline both materially impact net income.

Suzuken Co., Ltd. (9987.T) - Debt vs. Equity Structure

As of March 31, 2025, Suzuken Co., Ltd. reported total assets of ¥1,021,155 million and net assets of ¥271,567 million. The company's capital adequacy ratio improved to 26.6% (from 25.3% a year earlier), while the equity-to-asset ratio declined to 34.5% from 36.6%, reflecting shifts in capital composition and retained earnings usage.

• Share repurchases executed: 427,800 shares (June 2025) and 358,400 shares (September 2025).
• Repurchase program target: up to 5.2 million shares by March 2026 to enhance shareholder value and optimize capital structure.

The decrease in the equity-to-asset ratio to 34.5% signals a relative reduction in equity funding versus total assets, even as capital adequacy strengthened to 26.6%. Management's active buyback program and stated aim to maintain a balanced debt-to-equity profile point to a dual strategy: return capital to shareholders while keeping leverage within manageable bounds.

• Capital strength: rising capital adequacy ratio (26.6% vs 25.3% prior year).
• Liquidity/leverage stance: continued focus on maintaining balanced debt-to-equity; no signs of aggressive debt accumulation.

Related: Mission Statement, Vision, & Core Values (2026) of Suzuken Co., Ltd.

Suzuken Co., Ltd. (9987.T) Liquidity and Solvency

• Total cash: ¥141,581,991,936 (most recent quarter)
• Total assets: ¥1,146,413 million (as of June 30, 2025)
• Capital adequacy ratio: 35.1% (as of June 30, 2025)
• Dividend per share: increased from ¥40.00 to ¥50.00 for fiscal year ended March 31, 2025
• Extraordinary gain: ¥15,567 million from sale of investment securities (May-Oct 2025)

• Liquidity implications: the large cash balance supports operational needs, short-term obligations, and shareholder distributions.
• Solvency implications: a 35.1% capital adequacy ratio plus cash reserves provides comfort for long-term debt servicing and strategic flexibility.
• Dividend policy: history of dividends with a recent increase signals shareholder-friendly capital allocation backed by cash and realized gains.

Suzuken Co., Ltd. (9987.T) - Valuation Analysis

Suzuken Co., Ltd. (9987.T) displays valuation metrics that suggest the shares may be trading at a discount to fundamentals while offering mixed forward expectations from the market and analysts. Key headline figures:

• Market capitalization: ¥373.81 billion (as of July 1, 2025)
• Trailing P/E: 11.46
• Forward P/E: 16.79
• Price-to-sales (P/S): ¥0.16
• Price-to-book (P/B): ¥0.92
• Enterprise-to-revenue (EV/Revenue): 0.10
• Enterprise-to-EBITDA (EV/EBITDA): 4.76
• Year-to-date price performance: +30.67% (as of Nov 2025)

Implications for investors:

• Low trailing P/E (11.46) and EV/EBITDA (4.76) point to potential undervaluation versus peers if fundamentals hold.
• Forward P/E (16.79) is higher than trailing, implying either expected slower near-term earnings or market premium for projected growth.
• P/S of 0.16 and P/B below 1.0 (0.92) can signal balance-sheet support for the share price, but warrant scrutiny of asset quality and return on equity.
• Substantial YTD performance (+30.67%) indicates improving market sentiment; analyst targets remain dispersed (¥5,730-¥6,800), reflecting differing risk/reward views.

For strategic context on Suzuken's guiding principles and how its mission may influence long-term valuation, see: Mission Statement, Vision, & Core Values (2026) of Suzuken Co., Ltd.

Suzuken Co., Ltd. (9987.T) - Risk Factors

• Regulatory and pricing pressure

• Currency exchange volatility

• JPY depreciation of 10% vs USD/EUR could raise procurement cost for imported goods and compress gross margin by 0.5-1.5 percentage points (estimated impact on annual operating profit: ¥1-5 billion).

• Supply chain and inventory risk

• Demand cyclicality and macro sensitivity

• Technology, margin compression and competition

• Operational interruption from disasters or pandemics

• Balance-sheet and liquidity considerations

• Current ratio and net debt / EBITDA - deterioration here elevates refinancing risk.
• Days Inventory Outstanding (DIO) - each 10-20 day increase can require additional liquidity in the order of several billion yen.

Suzuken Co., Ltd. (9987.T) - Growth Opportunities

• Strategic pivot into healthcare-related services (community healthcare, nursing care support) to capture aging-population demand in Japan.
• Investment in development and manufacturing of medical equipment to diversify revenue beyond pharmaceutical distribution.
• Active share repurchase programs and Medium-Term Management Plan revisions aimed at optimizing capital structure and increasing shareholder returns.
• ESG initiatives focused on sustainable healthcare delivery, which align with long-term regulatory and market trends.

• Community healthcare and nursing care support: Suzuken is reallocating resources to develop integrated care services and local care networks, expecting increased recurring service revenue and cross-sell opportunities from its existing customer base of clinics and pharmacies.
• New business models: pilots include telehealth enablement, pharmacy-driven chronic care management, and bundled service offerings with partner providers and medical-device solutions.
• Medical-equipment development: targeted product lines (diagnostic devices, home-monitoring devices, nursing-care aids) aim to raise gross margin mix over time compared with low-margin wholesale distribution.
• Capital allocation & shareholder returns: the company's share repurchase programs (recent authorization: ¥10.0 billion) plus progressive dividend policy are designed to return excess capital while maintaining investment capacity for strategic projects.
• ESG & sustainability: initiatives focus on resilient supply chains, reduced environmental footprint in logistics, and improved access to care-factors likely to support tender wins, preferred-provider status, and institutional investor interest.